Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

DiaMedica Therapeutics (DMAC) Equity Ratio (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Equity Ratio readings, the most recent being 0.89 for Q1 2026.

  • Quarterly Equity Ratio rose 1.77% to 0.89 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.89 through Mar 2026, up 1.77% year-over-year, with the annual reading at 0.91 for FY2025, 4.06% up from the prior year.
  • Equity Ratio hit 0.89 in Q1 2026 for DiaMedica Therapeutics, down from 0.91 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.97 in Q1 2022 and bottomed at 0.86 in Q2 2025.
  • Average Equity Ratio over 5 years is 0.92, with a median of 0.93 recorded in 2022.
  • The largest annual shift saw Equity Ratio rose 5.22% in 2024 before it decreased 8.21% in 2025.
  • DiaMedica Therapeutics' Equity Ratio stood at 0.93 in 2022, then rose by 1.88% to 0.94 in 2023, then fell by 6.8% to 0.88 in 2024, then increased by 4.06% to 0.91 in 2025, then dropped by 2.67% to 0.89 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Equity Ratio are 0.89 (Q1 2026), 0.91 (Q4 2025), and 0.9 (Q3 2025).